National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix J: Prospects for Immunizing Against Herpesvirus varicellae." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
327
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

TABLE J.15 Disease Burden: Varicella and Herpes Zoster Infections in High-Risk Individuals

 

 

 

Under 1 Year

1–4 Years

5–14 Years

15–24 Years

25–59 Years

60 Years and Over

Morbidity Category

Description

Condition

Number of Cases

Duration

Number of cases

Duration

Number of Cases

Duration

Number of Cases

Duration

Number of Cases

Duration

Number of cases

Duration

A

Moderate localized pain, mild systemic reaction, or impairment requiring minor change in normal activities

 

 

 

 

 

 

 

 

 

 

 

 

 

B

Moderate pain or moderate impairment requiring moderate change in normal activities, e.g., housebound or in bed

 

 

 

 

 

 

 

 

 

 

 

 

 

C

Requiring hospitalization

Lymphomas leukamias; recipients of organ and bone marrow transplants

113

17

441

17

958

17

1,057

17

2,361

16

92

16

D

Mild chronic disability (not requiring hospitalization, institutionalization, or other major limitation of normal activity)

 

 

 

 

 

 

 

 

 

 

 

 

 

E

Moderate to severe chronic disability (requiring hospitalization, special care, or other major limitation of normal activity)

 

 

 

 

 

 

 

 

 

 

 

 

 

F

Total impairment

 

 

 

 

 

 

 

 

 

 

 

 

 

G

Reproductive impairment resulting in infertility

 

 

 

 

 

 

 

 

 

 

 

 

 

H

Death

 

9

n.a.

31

n.a.

70

n.a.

78

n.a.

169

n.a.

7

n.a.

Note: Duration are weighted averages

Page
327
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)